About This Trial

Novel bispecific antibody combining PD-1 and CTLA-4 blockade in single molecule.

Primary Endpoints

  • Overall survival
  • Progression-free survival

Latest Update

January 2026

Phase 2 showed 48% ORR in PD-L1 high patients. Pivotal Phase 3 enrollment progressing well.